• 2020
  Rosazza T, Lecoeur H, Blisnick T, Moya-Nilges M, Pescher P, Bastin P, Prina E, Späth GF, , Dynamic imaging reveals surface exposure of virulent Leishmania amastigotes during pyroptosis of infected macrophages., J Cell Sci 2020 06; 134(5): .
• 2020
  Baek KH, Piel L, Rosazza T, Prina E, Späth GF, No JH, , Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations., Pathogens 2020 May; 9(5): .
• 2020
  Smirlis D, Dingli F, Pescher P, Prina E, Loew D, Rachidi N, Späth GF, , SILAC-based quantitative proteomics reveals pleiotropic, phenotypic modulation in primary murine macrophages infected with the protozoan pathogen Leishmania donovani., J Proteomics 2020 02; 213(): 103617.
• 2020
  Lecoeur H, Prina E, Rosazza T, Kokou K, N'Diaye P, Aulner N, Varet H, Bussotti G, Xing Y, Milon G, Weil R, Meng G, Späth GF, , Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response., Cell Rep 2020 02; 30(6): 1870-1882.e4.
• 2020
  Lecoeur H, Rosazza T, Kokou K, Varet H, Coppée JY, Lari A, Commère PH, Weil R, Meng G, Milon G, Späth GF, Prina E, , Leishmania amazonensis Subverts the Transcription Factor Landscape in Dendritic Cells to Avoid Inflammasome Activation and Stall Maturation., Front Immunol 2020 ; 11(): 1098.
• 2019
  Lamotte S, Aulner N, Späth GF, Prina E, , Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening., Sci Rep 2019 01; 9(1): 438.
• 2016
  Chua MJ, Arnold MS, Xu W, Lancelot J, Lamotte S, Späth GF, Prina E, Pierce RJ, Fairlie DP, Skinner-Adams TS, Andrews KT, Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth, Int J Parasitol Drugs Drug Resist 2017 04;7(1):42-50.
• 2016
  Bendjeddou LZ, Loaëc N, Villiers B, Prina E, Späth GF, Galons H, Meijer L, Oumata N, Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor, Eur J Med Chem 2017 Jan;125:696-709.
• 2016
  Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K, Aulner N, Defontaine A, No JH, Ruchaud S, Skaltsounis AL, Galons H, Späth GF, Meijer L, Rachidi N, , From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity., Antimicrob Agents Chemother 2016 05; 60(5): 2822-33.
• 2014
  Forestier CL, Späth GF, Prina E, Dasari S, Simultaneous multi-parametric analysis of Leishmania and of its hosting mammal cells: A high content imaging-based method enabling sound drug discovery process, Microb. Pathog. 2014 Oct;.
• 2014
  Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, Prina E, Cayla M, Descoteaux A, Späth GF, , Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses., Mol Microbiol 2014 Jul; 93(1): 146-66.
• 2014
  Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF, , Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection., Antimicrob Agents Chemother 2014 ; 58(3): 1501-15.
• 2012
  Horjales S, Schmidt-Arras D, Limardo RR, Leclercq O, Obal G, Prina E, Turjanski AG, Späth GF, Buschiazzo A, , The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms., Structure 2012 Oct; 20(10): 1649-60.